Difference between revisions of "Team:CPU CHINA"

Line 31: Line 31:
 
          
 
          
  
−
             <div class="page page1">
+
             <center class="page page1">
−
            <center>
+
 
             <img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300">
 
             <img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300">
 
             </center>
 
             </center>
−
            </div>
 
  
−
            <div class="page page2">
 
 
             <h5>Our HEAD-Treg</h5>
 
             <h5>Our HEAD-Treg</h5>
−
             <center>
+
             <center class="page page2">
 
             <video src="https://static.igem.org/mediawiki/2017/1/14/T--CPU_CHINA--mainpagevideo.mp4" controls="controls" class="video" width = "60%"></video>
 
             <video src="https://static.igem.org/mediawiki/2017/1/14/T--CPU_CHINA--mainpagevideo.mp4" controls="controls" class="video" width = "60%"></video>
 
             </center>
 
             </center>
−
            </div>
 
  
−
            <div class="page page3">
 
 
             <center><h3>Description</h3></center>
 
             <center><h3>Description</h3></center>
  
Line 54: Line 49:
 
                     inflammatory environment, which enables them to play their role of immunosuppression in lesions more
 
                     inflammatory environment, which enables them to play their role of immunosuppression in lesions more
 
                     efficiently and more stably. <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4></center>
 
                     efficiently and more stably. <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4></center>
−
 
−
            </div>
 
−
 
  
 
         </div>
 
         </div>

Revision as of 11:54, 1 November 2017

Our HEAD-Treg

Description


Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease.
It is of great essence to develop a novel cell-targeted therapy for RA because there is no radical cure for RA for the time being.
To solve the problems existing in the current treatment of RA, we design and build a brand new immunotherapy.
FOXP3+ regulatory T cells(Tregs), which can suppress and regulate immune reactions, are modified
utilizing a lentiviral vector system to express a chimeric antigen receptor(CAR) targeting inflammatory cells associated with RA.
Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the inflammatory environment, which enables them to play their role of immunosuppression in lesions more efficiently and more stably.
These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect.